CA
NZ
UK
AU
IND
US
Beyond Meat, which also calls itself Beyond The Plant Protein Company, reported results for its third quarter ended September 26, 2026. All figures were retroactively adjusted for a 1-for-30Reverse Stock Spliteffective August 13, 2026.
Biomea develops novel small molecule therapies for metabolic diseases, with a focus on diabetes and obesity. Its approach uses covalent small molecules, which are synthetic compounds that form a permanent bond to a target protein.
BioNexus operates healthcare diagnostics through MRNA Scientific Sdn. Bhd., specialty chemicals through Chemrex Corporation Sdn. Bhd., andInvestmentand strategic development activities.
Bone Biologics focuses on bone regeneration in spinal fusion using NELL-1, a recombinant human protein used with demineralized bone matrix. The filing describes the combination as an osteopromotive product that provides target specific control over bone regeneration.
The filing states that it does not reflect the business combination, which closed later. As of July 17, 2026, there were approximately 9,409,633 shares of Class A common stock and 232,083,710 shares of Class B common stock outstanding.
Boxlight designs, produces and distributes interactive displays, collaboration software and related products for schools, education,Businessand government interactive spaces.
Bridger provides aerial wildfire surveillance, relief and suppression, and aerial firefighting services primarily in the United States, along with airframe modification and integration solutions for government customers.
On October 6, 2026, the company announced that its board approved a restructuring on October 2, 2026 while it conducts a process to explore strategic alternatives to maximize stockholder value. The restructuring includes the planned discontinuation ofClinical Trialsand further development of two allogeneic CAR-T …
Revenue was USD 18,440,210 against USD 16,965,658 a year earlier.Gross Profitwas USD 7,696,790 against USD 7,370,506, and total operating expenses were USD 8,889,932 against USD 8,012,907.
Cerenome is a U.S. healthcare company focused on central nervous system cancers through threeBusinessareas: precision diagnostics, targeted radiopharmaceutical therapeutics and proprietary data analytics. Effective August 3, 2026, it filed an amendment to change its name from Plus Therapeutics.
Please wait processing your request...